Scarica l'app Stockscreener
166.80
10.08%
-18.70
Pre-mercato:
167.39
0.59
+0.35%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Storia dei dividendi
Precedente Chiudi:
$185.50
Aprire:
$184.34
Volume 24 ore:
4.59M
Relative Volume:
3.86
Capitalizzazione di mercato:
$16.77B
Reddito:
$3.10B
Utile/perdita netta:
$668.60M
Rapporto P/E:
25.64
EPS:
6.5044
Flusso di cassa netto:
$831.30M
1 W Prestazione:
-5.10%
1M Prestazione:
-1.03%
6M Prestazione:
+22.59%
1 anno Prestazione:
+30.08%
Intervallo 1D:
$164.56
$185.55
Intervallo di 1 settimana:
$164.56
$186.12
Portata 52W:
$122.14
$186.12
Neurocrine Biosciences Inc Stock (NBIX) Company Profile
Nome
Neurocrine Biosciences Inc
Settore
Telefono
(858) 617-7600
Indirizzo
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Compare NBIX vs TAK, HLN, TEVA, ZTS, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NBIX
Neurocrine Biosciences Inc
|
166.80 | 17.74B | 3.10B | 668.60M | 831.30M | 6.5044 |
TAK
Takeda Pharmaceutical Co Adr
|
17.10 | 55.69B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.855 | 43.77B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
35.01 | 36.19B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
77.28 | 32.25B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
517.71 | 26.29B | 3.17B | 1.29B | 1.01B | 27.09 |
Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-24 | Iniziato | Wolfe Research | Outperform |
| 2026-01-08 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-10-21 | Iniziato | Citigroup | Buy |
| 2025-07-21 | Iniziato | Truist | Buy |
| 2025-07-10 | Iniziato | Goldman | Buy |
| 2025-04-15 | Aggiornamento | Needham | Hold → Buy |
| 2025-04-14 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-02-11 | Iniziato | Deutsche Bank | Hold |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-08-29 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2024-04-24 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-12-13 | Ripresa | Citigroup | Neutral |
| 2023-12-12 | Iniziato | Deutsche Bank | Buy |
| 2023-10-24 | Ripresa | Cantor Fitzgerald | Overweight |
| 2023-08-21 | Reiterato | Mizuho | Neutral |
| 2023-07-24 | Aggiornamento | SVB Securities | Market Perform → Outperform |
| 2023-07-06 | Aggiornamento | BMO Capital Markets | Underperform → Market Perform |
| 2023-05-04 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-03-30 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2023-03-03 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2023-02-03 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-11-14 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-10-11 | Iniziato | UBS | Buy |
| 2022-09-26 | Iniziato | Wells Fargo | Equal Weight |
| 2022-06-06 | Ripresa | Jefferies | Buy |
| 2022-03-03 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-02-25 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-01-18 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-11-19 | Iniziato | BMO Capital Markets | Underperform |
| 2021-11-17 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-10-14 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | Ripresa | Needham | Hold |
| 2021-08-06 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2021-05-18 | Ripresa | Goldman | Neutral |
| 2021-05-06 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2021-02-02 | Iniziato | Raymond James | Outperform |
| 2020-09-30 | Iniziato | The Benchmark Company | Hold |
| 2020-08-04 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-06-29 | Downgrade | Goldman | Buy → Neutral |
| 2020-06-09 | Iniziato | Wedbush | Outperform |
| 2020-03-06 | Iniziato | Citigroup | Buy |
| 2020-02-27 | Iniziato | Barclays | Equal Weight |
| 2020-02-24 | Iniziato | William Blair | Outperform |
| 2020-02-06 | Iniziato | Mizuho | Neutral |
| 2020-02-05 | Reiterato | H.C. Wainwright | Buy |
| 2019-12-13 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2019-08-07 | Iniziato | RBC Capital Mkts | Outperform |
| 2019-07-16 | Iniziato | Oppenheimer | Outperform |
| 2019-06-05 | Iniziato | Guggenheim | Neutral |
| 2019-05-21 | Iniziato | Credit Suisse | Outperform |
| 2019-04-22 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2019-02-06 | Reiterato | BofA/Merrill | Buy |
| 2019-01-23 | Downgrade | JP Morgan | Overweight → Neutral |
| 2018-12-13 | Iniziato | Goldman | Buy |
| 2018-11-21 | Iniziato | Canaccord Genuity | Buy |
Mostra tutto
Neurocrine Biosciences Inc Borsa (NBIX) Ultime notizie
Neurocrine Biosciences stock hits all-time high at 181.3 USD - Investing.com
NBIX|Neurocrine Biosciences Inc|Price:176.825|Chg%:+1.055 - TradingKey
Enterprise value to revenue forward of Neurocrine Biosciences, Inc. – HAM:NB3 - TradingView
Net margin % of Neurocrine Biosciences, Inc. – HAM:NB3 - TradingView
Neurocrine Biosciences, Inc. Revenue Breakdown – HAM:NB3 - TradingView
JPMorgan discloses 6.3% Neurocrine stake in 13G/A filing (NBIX) - Stock Titan
Neurocrine Gears Up to Report Q2 Earnings: What's in the Cards? - TradingView
Weekly Recap: Guggenheim hikes NBIX price target and Siddhanti named CBO - TradingView
Neurocrine Biosciences (NASDAQ:NBIX): Strong Growth Stock with Technical Breakout Setup - ChartMill
SLNO Stock Soars Over 39% — What’s Fueling The Rally? - Stocktwits
Neurocrine Biosciences (NBIX) Refreshes Leadership On A Narrative That Still Sees Undervaluation - simplywall.st
Neurocrine Biosciences (NASDAQ:NBIX) Screens as a High Growth Stock - ChartMill
How Investors Are Reacting To Neurocrine Biosciences (NBIX) Leadership Hires In Business And Market Access - simplywall.st
Neurocrine Biosciences Names New Senior Vice Presidents - Contract Pharma
Neurocrine Biosciences Inc (NBIX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
NEUROCRINE BIOSCIENCES INC. R (NB3.F) Q1 FY2026 earnings call transcript - Yahoo Finance
Neurocrine Biosciences, Inc. (NBIX) Stock Forecasts - Yahoo! Finance Canada
Neurocrine bolsters senior ranks as it builds beyond Ingrezza - The Pharma Letter
NBIX: Neurocrine Biosciences, Inc. Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Neurocrine Biosciences Inc (NBIX) Institutional Confidence - TradingKey
Neurocrine Biosciences names three senior vice presidents - Investing.com
Neurocrine Biosciences names three senior vice presidents By Investing.com - Investing.com Nigeria
Neurocrine Hires Market Access Chief, Promotes Two Executives - Stock Titan
Neurocrine Biosciences (NBIX) Stock Trades Fair On Earnings But Mixed On Value - Yahoo Finance
Neurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Yahoo Finance
Neurocrine Biosciences (NBIX) Appoints Samir Siddhanti To Lead Growth After $2.9 Billion Deal - simplywall.st
Neurocrine Biosciences (NBIX) Appoints Samir Siddhanti As Chief Business Officer - Yahoo Finance
NBIX stock consolidates after solid 2024 guidance and Ingrezza growth - Ad-hoc-news.de
Neurocrine Biosciences Appoints Samir Siddhanti as Chief Business Officer - Contract Pharma
Neurocrine Biosciences Inc (NBIX) Stock Up 3.5% and Still Underv - GuruFocus
Neurocrine Biosciences Appoints Samir Siddhanti Chief Business Officer - TradingView
Neurocrine Biosciences names Siddhanti chief business officer By Investing.com - Investing.com South Africa
Neurocrine Biosciences names Siddhanti chief business officer - Investing.com
Neurocrine Biosciences names Samir Siddhanti chief business officer - StreetInsider
Neurocrine executive who led $2.9B Soleno deal gets new role - Stock Titan
Neurocrine Biosciences appoints Samir Siddhanti as Chief Business Officer - scanx.trade
Neurocrine Biosciences (NASDAQ:NBIX) Offers a High Growth Momentum Breakout Setup - ChartMill
Alnylam Stock And 2 US Health Care Names With Earnings In Focus - Sahm
Understanding Momentum Shifts in (NBIX) - Stock Traders Daily
Neurocrine Biosciences (NBIX) Stock Looks Reasonable At Today’s Price - simplywall.st
Is Neurocrine Biosciences (NBIX) Still Undervalued Or Does Its P E Leave Little Upside? - simplywall.st
NEUROCRINE BIOSCIENCES, INC. : WELLS FARGO RAISES TARGET PRICE TO $200 FROM $175 - Bitget
Price to sales forward of Neurocrine Biosciences, Inc. – NASDAQ:NBIX - TradingView
NBIX Maintained by Wells Fargo -- Price Target Raised to $200 - GuruFocus
Wells Fargo Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Raises Target Price to $200 - Moomoo
Should Strong Earnings Projections and Zacks Rank #1 Status Require Action From Neurocrine Biosciences (NBIX) Investors? - simplywall.st
Zacks.com featured highlights include NVIDIA, Neurocrine Biosciences and Ball - The Globe and Mail
Neurocrine Biosciences (NASDAQ:NBIX) Fits the Growth at a Reasonable Price Mold of Peter Lynch Screening - ChartMill
BofA Securities Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Announces Target Price $199 - Moomoo
Neurocrine Biosciences Inc (NBIX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Can Neurocrine (NBIX) Run Higher on Rising Earnings Estimates? - Yahoo Finance
Neurocrine Biosciences Inc Azioni (NBIX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Neurocrine Biosciences Inc Azioni (NBIX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Norwalk Leslie V | Director |
Jul 28 '26 |
Sale |
182.01 |
1,250 |
227,508 |
1,588 |
| Delaet Ingrid | Chief Regulatory Officer |
Jul 10 '26 |
Option Exercise |
106.02 |
4,367 |
462,989 |
20,592 |
| Delaet Ingrid | Chief Regulatory Officer |
Jul 10 '26 |
Sale |
181.02 |
4,367 |
790,514 |
16,225 |
| Lippoldt Darin | Chief Legal Officer |
Jul 09 '26 |
Option Exercise |
81.49 |
10,000 |
814,900 |
64,729 |
| Lippoldt Darin | Chief Legal Officer |
Jul 09 '26 |
Sale |
179.60 |
10,000 |
1,796,014 |
54,729 |
0.25%
0.17%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):